Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
Liver-directed small interfering RNA (siRNA) therapeutics that silence INHBE are advancing as next-generation anti-obesity agents
Sikiri & Hahm et al
Looking at the full picture, including ongoing stress and anxiety symptoms that affect daily life, helps a provider decide where peptides fit and where other support matters more
CJC-1295/ipamorelin and Sermorelin serve a different role: they elevate growth hormone and IGF-1 systemically to support the broader repair environment rather than targeting a specific injury site
The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis (Bays et al., NEJM 2025) reported 28.7% mean weight loss at 68 weeks at the 12 mg dose, plus a 75.8% reduction in WOMAC knee pain scores
US$ 23.40
US$ 28.49
US$ 29.81
US$ 23.89
